Menu Back toAnalyzing-Innovation-s-Progress-in-the-Gottlieb-Era

DIA 2018 Global Annual Meeting

Analyzing Innovation’s Progress in the Gottlieb Era

    Session Chair(s)
      Nancy Bradish Myers, JD

      Nancy Bradish Myers, JD

      • President and Founder
      • Catalyst Healthcare Consulting, Inc, United States
    FDA Commissioner Scott Gottlieb has advanced an ambitious plan to modernize drug development and FDA’s approach to regulation. He has taken bold new approaches to streamline clinical trials, engage in efficient, risk-based regulation, and advance innovation.

    Gottlieb is focused on transformative innovations that hold the promise of both significantly impacting disease and reducing overall health care costs.

    How is the agency’s approach impacting innovation? Is it making a difference? Are further changes needed? What does the future of drug development look like under Gottlieb? Where are the key opportunities for collaboration between FDA and industry?

    This DIAmond Session will bring together top regulatory thought leaders from FDA, industry and the venture capital world, for an interactive, forward-looking discussion of FDA’s modernization plan and its impact on development of innovative therapies.
    Learning Objective : Describe FDA’s Medical Innovation Development Plan; Identify implications for the future of drug development under Commissioner Gottlieb; Plan for impact of regulatory changes on drug development and business plans.
      Sandra A. Milligan, DIAFellow, JD, MD


      Sandra A. Milligan, DIAFellow, JD, MD

      • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety
      • Merck Research Laboratories, United States